Nadmierny wzrost bakterii w jelicie cienkim - zalecane diety dla zespołu SIBO

Small Intestinal Bacterial Overgrowth Syndrome (SIBO) represents a pathological condition characterized by the abnormal proliferation of bacterial strains within the small intestine—either through the colonization of microorganisms that are not typically present under physiological conditions or through the excessive multiplication of bacteria that normally reside there in only trace quantities. This dysregulated microbial growth gives rise to a constellation of distressing gastrointestinal symptoms in affected individuals, including recurrent abdominal pain, alternating episodes of constipation and diarrhea, troublesome gastroesophageal reflux, excessive flatulence, and abdominal distension. Beyond the digestive tract, SIBO may also manifest with extrasintestinal symptoms, such as depressive episodes, chronic fatigue syndrome, inflammatory joint discomfort, and various dermatological abnormalities. The etiology of SIBO is multifactorial and intricate, with common contributing factors encompassing reduced gastric acid secretion (achlorhydria), pancreatic enzyme deficiencies, immunological dysfunctions, and structural anomalies within the gastrointestinal tract—such as strictures, neoplastic lesions of the small intestine, or the presence of diverticula. Furthermore, SIBO frequently coexists with other medical conditions, including celiac disease, Crohn’s disease, chronic liver disorders, and diabetic neuropathy. The management of SIBO presents a clinical challenge due to the complexity of its underlying mechanisms and the propensity for recurrence. Conventional therapeutic approaches primarily rely on targeted antibiotic regimens, commonly employing agents such as metronidazole, doxycycline, and rifaximin, which have demonstrated efficacy in reducing the excessive bacterial load. However, an equally critical and complementary component of treatment involves the implementation of a carefully tailored dietary strategy, the primary objectives of which are to restore microbial equilibrium within the small intestine and alleviate the characteristic clinical manifestations associated with SIBO.

The management of Small Intestinal Bacterial Overgrowth (SIBO) necessitates specialized nutritional interventions alongside targeted antimicrobial pharmacotherapy. The most widely recognized therapeutic frameworks include the low-FODMAP diet, the Specific Carbohydrate Diet (SCD), the Gut and Psychology Syndrome (GAPS) diet, and Dr. Allison Siebecker’s SIBO-specific protocol. The low-FODMAP protocol aims to restrict fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. Because these short-chain carbohydrates are poorly absorbed in the small intestine, they undergo rapid fermentation by ectopic bacteria, producing hydrogen, methane, and short-chain fatty acids, which cause significant visceral hypersensitivity, abdominal pain, and bloating. The protocol comprises three distinct phases: strict elimination (lasting 2 to 6 weeks), systematic reintroduction to assess individual tolerance thresholds, and long-term dietary personalization. The Specific Carbohydrate Diet (SCD) operates on the complete exclusion of complex carbohydrates—disaccharides and polysaccharides such as sucrose, lactose, and starches—allowing predominantly simple monosaccharides, lean proteins, and healthy fats. Monosaccharides do not require extensive brush-border enzymatic cleavage and are rapidly absorbed in the proximal jejunum, effectively depriving small intestinal bacterial colonies of essential fermentable substrates. Permitted foods on SCD include fresh meats, fish, eggs, lactose-free fermented cheeses, non-starchy vegetables, and specific legumes, while grains, starchy tubers (potatoes, sweet potatoes), and processed sweeteners are excluded. The GAPS diet, developed by Dr. Natasha Campbell-McBride, builds upon SCD principles through an intensive six-stage progression designed to restore mucosal integrity. Early stages emphasize gelatin-rich bone broths, healthy animal fats, and gradual introduction of fermented juices, progressively incorporating gentle stewed vegetables, avocado, eggs, and cooked meats before reaching the full maintenance stage. Dr. Allison Siebecker’s SIBO Specific Food Guide synthesizes elements of both SCD and low-FODMAP protocols. Tailored specifically for patients with high gastrointestinal reactivity, it emphasizes peeled, well-cooked, pureed ingredients during initial phases and establishes gradual food reintroduction over a multi-month period. Because these restrictive dietary protocols carry inherent risks of micronutrient deficiencies, they must be conducted under the structured supervision of a qualified clinical dietitian and adjusted dynamically to clinical progress.